Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andy Patton who started this subject	11/22/2002 6:44:41 PM
From: nigel bates	Read Replies (1) of 236

Just parking - biorex.hu Biorex is a young pharmaceutical research and development company based in Hungary. It is developing innovative pharmaceutical products based on proprietary Heat Shock Protein (HSP) co-induction technology. Biorex's main development focus is on the treatment of chronic vascular disease and its first products in clinical development are targeted at endothelial dysfunction (the precursor to atherosclerosis and cardiovascular disease) and diabetic complications. It also has pre-clinical development projects in the areas of neurodegenerative diseases, neuroregeneration, insulin resistance and wound healing - all poorly served therapeutic areas of high commercial value. Its lead compound for endothelial dysfunction, BRX-235 will shortly complete a Phase II study and BRX-345, for diabetic complications, is about to enter Phase I trials... September 2002 - A Biorex researcher, Judit Hargitai received the "Best poster" award for the identification of heat shock factor-1 (HSF-1) as a target of BRX-molecules on the EMBO Course on "The biology of the heat shock proteins and molecular chaperones"

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next